GlassScriptPhysician profile
Sarah E Vellotti
NPI 1760880678
$6,699.27
in general payments reported to CMS, 2019-2025
37 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,777 · 2022: $2,326 · 2023: $1,316 · 2024: $776 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,439.66 | 2021-2023 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $842.59 | 2021-2023 | Trelegy Ellipta, Bexsero, Nucala |
| Corium, LLC | $504.92 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $496.77 | 2024-2025 | Qelbree |
| Regeneron Healthcare Solutions, INC. | $420.79 | 2021-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $394.70 | 2021-2023 | Glassia, Cuvitru |
| Genzyme Corporation | $335.40 | 2022-2023 | |
| Optinose US, INC. | $332.91 | 2021-2023 | |
| Mylan Specialty L.P. | $244.93 | 2021-2022 | |
| Amgen INC. | $206.60 | 2021-2023 | Tezspire |
| Genentech USA, INC. | $194.11 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $170.49 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.73 | 2021-2023 | Ofev, Spiriva Respimat |
| Abbvie INC. | $140.16 | 2022-2023 | |
| Grifols USA, LLC | $105.57 | 2021-2023 | Prolastin-C Liquid, Xembify |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $69.36 | 2023 | Opsumit, Uptravi |
| Tris Pharma INC | $69.17 | 2025 | Onyda Xr, Dyanavel Xr |
| Aimmune Therapeutics, INC. | $55.07 | 2022 | |
| Merck Sharp & Dohme LLC | $54.63 | 2024-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Alk-Abello, INC | $49.21 | 2021 | |
| Collegium Pharmaceutical, INC. | $46.84 | 2025 | Jornay Pm |
| Biocryst US Sales Co., LLC | $42.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.54 | 2021-2023 | |
| Pfizer INC. | $33.48 | 2022-2025 | |
| Organon LLC | $31.61 | 2024-2025 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $30.23 | 2024 | |
| Insmed, INC. | $29.13 | 2023 | Arikayce |
| Ani Pharmaceuticals, INC. | $22.29 | 2023 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $21.30 | 2021 | |
| United Therapeutics Corporation | $21.19 | 2023 | Tyvaso |
| Covis Pharma Gmbh | $18.80 | 2022 | |
| Cranial Technologies, INC | $18.06 | 2025 | Doc Band |
| Baxter Healthcare | $17.32 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Vertical Pharmaceuticals, LLC | $15.87 | 2024 | Relexxii |
| Avion Pharmaceuticals | $15.76 | 2023 | Methylphenidate Hydrochloride |
| Sanofi Pasteur INC. | $15.03 | 2025 | |
| Pharming Healthcare, INC. | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Vellotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.